fifti
year
identif
jean
lindenmann
alick
isaac
year
sinc
first
produc
recombin
form
lab
charl
weissmann
year
follow
approv
hoffmannla
roch
roferon
ifn
stranglehold
antivir
market
biolog
might
final
loosen
new
gener
biotech
firm
focus
antibodi
treatment
nucleic
acid
therapi
target
cellular
protein
well
viral
compon
progress
slow
fit
combin
rapidli
adapt
elus
viral
pathogen
profus
new
therapeut
strategi
novel
target
could
spell
troubl
clinic
illustr
focu
fund
princip
sponsor
pfizer
support
sponsor
gilead
scienc
vast
major
antivir
treatment
approv
small
molecul
target
limit
number
viral
enzym
hegemoni
small
molecul
surpris
virus
intracellular
parasit
limit
antibodi
biolog
penetr
cell
membran
well
known
addit
heterogen
mani
viral
pathogen
hepat
c
viru
hcv
six
differ
major
genotyp
vari
sequenc
much
propens
mutat
hiv
evolv
day
made
difficult
identifi
crossreact
antibodi
abl
neutral
varieti
primari
isol
one
reason
mani
biotech
firm
develop
either
polyclon
antibodi
approach
cocktail
two
monoclon
antibodi
mab
target
differ
viral
epitop
sever
technolog
breakthrough
howev
help
matter
uniqu
viral
genom
alreadi
lodg
genbank
advanc
sequenc
technolog
transform
abil
character
emerg
viral
pathogen
resequ
exist
one
look
drug
resist
chang
receptor
tropism
mark
progress
genom
sequenc
sar
sever
acquir
respiratori
syndrom
coronaviru
obtain
mere
six
day
follow
isol
viral
nucleic
acid
time
abil
assembl
megabas
sequenc
synthes
viral
genom
progress
apac
work
reconstitut
polioviru
synthet
fragment
recent
creation
hybrid
influenza
viru
contain
eight
gene
pandem
strain
provid
key
insight
virul
factor
hostviru
interact
p
largescal
highthroughput
omic
approach
studi
influenc
viral
infect
host
cell
gene
express
protein
composit
metabolit
etc
also
yield
new
target
reveal
insight
process
time
viral
life
cycl
pathogenesi
studi
aid
breakthrough
viru
cultur
illustr
demonstr
two
year
ago
function
hcv
genom
replicon
produc
robust
level
infecti
viru
cell
cultur
advanc
contribut
increas
understand
viral
infect
erad
recent
progress
slow
although
abil
viral
rna
dna
activ
ifn
product
report
isaac
back
took
four
decad
identifi
role
tolllik
receptor
tlr
sens
viral
infect
rigi
recent
identifi
cytoplasm
sensor
viral
rna
dai
first
report
cytosol
sensor
viral
dna
report
octob
natur
also
know
key
actor
mediat
antivir
activ
type
ifn
respons
includ
protein
kinas
pkr
synthetasernas
l
system
adenosin
deaminas
mx
gtpase
also
cellular
microrna
natur
new
member
expand
ifn
protein
famili
eg
recent
identifi
type
iii
interleukin
also
turn
therapi
suggest
sampl
tip
therapeut
iceberg
term
host
target
host
protein
mean
lack
select
pressur
viru
evolv
resist
unlik
tradit
therapi
bind
viral
protein
addit
mani
direst
outcom
viral
diseas
due
aberr
host
immun
respons
eg
cytokin
storm
elicit
influenza
ebola
viru
possibl
reduc
sever
respons
patient
outcom
might
improv
address
host
protein
coopt
differ
type
viral
pathogen
broadspectrum
agent
might
also
creat
maxim
commerci
potenti
compani
facilit
treatment
select
physician
one
underestim
difficulti
move
antivir
clinic
first
complex
human
biolog
mean
task
identifi
key
point
medic
intervent
could
difficult
simpl
viral
target
drug
target
essenti
integr
cellular
protein
may
also
induc
harsher
side
effect
although
insurmount
indic
current
antivir
treatment
exactli
nontox
perhap
seriou
concern
pauciti
anim
model
replic
pathogenesi
human
diseas
make
antivir
r
entir
differ
prospect
antibacteri
preclin
studi
often
good
predictor
clinic
efficaci
best
larg
anim
model
hiv
exampl
simian
immunodefici
viru
infect
macaqu
chimpanze
inject
hiv
fail
develop
humanlik
diseas
recogn
limit
model
look
recent
highprofil
failur
merck
hiv
trival
monkey
studi
predict
would
protect
supplant
domin
ifn
exist
small
molecul
approv
antivir
market
easi
encourag
last
mani
differ
approach
progress
clinic
invest
big
pharma
biotech
deadli
pathogen
evolv
millennia
elud
human
immun
defens
therapeut
avenu
avail
break
cycl
infect
better
